820 related articles for article (PubMed ID: 24084650)
1. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease.
Lautenschläger C; Schmidt C; Lehr CM; Fischer D; Stallmach A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):578-86. PubMed ID: 24084650
[TBL] [Abstract][Full Text] [Related]
2. Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients.
Schmidt C; Lautenschlaeger C; Collnot EM; Schumann M; Bojarski C; Schulzke JD; Lehr CM; Stallmach A
J Control Release; 2013 Jan; 165(2):139-45. PubMed ID: 23127508
[TBL] [Abstract][Full Text] [Related]
3. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies.
Coco R; Plapied L; Pourcelle V; Jérôme C; Brayden DJ; Schneider YJ; Préat V
Int J Pharm; 2013 Jan; 440(1):3-12. PubMed ID: 22820482
[TBL] [Abstract][Full Text] [Related]
4. Budesonide Loaded PLGA Nanoparticles for Targeting the Inflamed Intestinal Mucosa--Pharmaceutical Characterization and Fluorescence Imaging.
Ali H; Weigmann B; Collnot EM; Khan SA; Windbergs M; Lehr CM
Pharm Res; 2016 May; 33(5):1085-92. PubMed ID: 26718953
[TBL] [Abstract][Full Text] [Related]
5. Surface-functionalized, pH-responsive poly(lactic-co-glycolic acid)-based microparticles for intranasal vaccine delivery: Effect of surface modification with chitosan and mannan.
Li Z; Xiong F; He J; Dai X; Wang G
Eur J Pharm Biopharm; 2016 Dec; 109():24-34. PubMed ID: 27569030
[TBL] [Abstract][Full Text] [Related]
6. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery.
Parveen S; Sahoo SK
Eur J Pharmacol; 2011 Nov; 670(2-3):372-83. PubMed ID: 21951969
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of Cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model.
Melero A; Draheim C; Hansen S; Giner E; Carreras JJ; Talens-Visconti R; Garrigues TM; Peris JE; Recio MC; Giner R; Lehr CM
Eur J Pharm Biopharm; 2017 Oct; 119():361-371. PubMed ID: 28709903
[TBL] [Abstract][Full Text] [Related]
8. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases.
Ali H; Weigmann B; Neurath MF; Collnot EM; Windbergs M; Lehr CM
J Control Release; 2014 Jun; 183():167-77. PubMed ID: 24685705
[TBL] [Abstract][Full Text] [Related]
9. Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease.
Leonard F; Srinivasan S; Liu X; Collnot EM; Ferrari M; Lehr CM; Godin B
Eur J Pharm Biopharm; 2020 Jun; 151():61-72. PubMed ID: 32283213
[TBL] [Abstract][Full Text] [Related]
10. Ultrafine PEG-coated poly(lactic-co-glycolic acid) nanoparticles formulated by hydrophobic surfactant-assisted one-pot synthesis for biomedical applications.
Chu CH; Wang YC; Huang HY; Wu LC; Yang CS
Nanotechnology; 2011 May; 22(18):185601. PubMed ID: 21415469
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and characterization of tumor-targeted copolymer nanocarrier modified by transferrin.
Liu R; Wang Y; Li X; Bao W; Xia G; Chen W; Cheng J; Xu Y; Guo L; Chen B
Drug Des Devel Ther; 2015; 9():2705-19. PubMed ID: 26045659
[TBL] [Abstract][Full Text] [Related]
12. Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease.
Griga T; Voigt E; Gretzer B; Brasch F; May B
Hepatogastroenterology; 1999; 46(26):920-3. PubMed ID: 10370639
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery nano/micro particles to inflamed intestinal mucosa in human.
Park K
J Control Release; 2013 Jan; 165(2):162. PubMed ID: 23265297
[No Abstract] [Full Text] [Related]
14. Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises.
Ungaro F; d'Angelo I; Miro A; La Rotonda MI; Quaglia F
J Pharm Pharmacol; 2012 Sep; 64(9):1217-35. PubMed ID: 22881435
[TBL] [Abstract][Full Text] [Related]
15. Surface-functionalized polymethacrylic acid based hydrogel microparticles for oral drug delivery.
Sajeesh S; Bouchemal K; Sharma CP; Vauthier C
Eur J Pharm Biopharm; 2010 Feb; 74(2):209-18. PubMed ID: 19737614
[TBL] [Abstract][Full Text] [Related]
16. Swellable hydrogel particles for controlled release pulmonary administration using propellant-driven metered dose inhalers.
Selvam P; El-Sherbiny IM; Smyth HD
J Aerosol Med Pulm Drug Deliv; 2011 Feb; 24(1):25-34. PubMed ID: 20961166
[TBL] [Abstract][Full Text] [Related]
17. Haloperidol-loaded intranasally administered lectin functionalized poly(ethylene glycol)-block-poly(D,L)-lactic-co-glycolic acid (PEG-PLGA) nanoparticles for the treatment of schizophrenia.
Piazza J; Hoare T; Molinaro L; Terpstra K; Bhandari J; Selvaganapathy PR; Gupta B; Mishra RK
Eur J Pharm Biopharm; 2014 May; 87(1):30-9. PubMed ID: 24560967
[TBL] [Abstract][Full Text] [Related]
18. In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles.
Semete B; Booysen LI; Kalombo L; Venter JD; Katata L; Ramalapa B; Verschoor JA; Swai H
Toxicol Appl Pharmacol; 2010 Dec; 249(2):158-65. PubMed ID: 20851137
[TBL] [Abstract][Full Text] [Related]
19. Analysis of direct tissue isoelectric focused protein profiles of resected intestinal mucosa and endoscopic biopsies from patients with inflammatory bowel disease.
Szewczuk MR; Depew WT
Clin Invest Med; 1992 Feb; 15(1):49-59. PubMed ID: 1374000
[TBL] [Abstract][Full Text] [Related]
20. Poly aspartic acid peptide-linked PLGA based nanoscale particles: potential for bone-targeting drug delivery applications.
Jiang T; Yu X; Carbone EJ; Nelson C; Kan HM; Lo KW
Int J Pharm; 2014 Nov; 475(1-2):547-57. PubMed ID: 25194353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
